Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) has released an update.
ResMed Inc’s Chief Financial Officer, Brett Sandercock, has reported a transaction under a Rule 10b5-1 plan, involving the sale of 1,000 shares of company stock at a price of $233.47 per share. Following the transaction, Sandercock’s direct beneficial ownership in the company stands at 95,812 shares. The transaction, dated October 8, 2024, was executed in accordance with a pre-established trading plan adopted on February 6, 2024.
For further insights into AU:RMD stock, check out TipRanks’ Stock Analysis page.
